A recent study in a cohort of patients with gliomas of various grades evaluated the efficacy of serum DNA for the concurrent detection of the loss of chromosomal heterozygosity and O(6)-methylguanine-DNA methyltransferase (MGMT) methylation. This evidence concerns the gene MGMT and central nervous system cancer.